Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
6 Emerging clinical applications 6.1 Non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) Studies investigating GLP-1 receptor agonists for the prevention of NAFLD/NASH indicate potential effectiveness via several molecular mechanisms
PMC 4545271
Artigas CF, Stokes V, Tan GD, Theodorakis MJ
Those who started at 4mg saw faster initial appetite effects but also experienced higher rates of nausea and other gastrointestinal side effects
doi:10.1016/j.rmed.2013.09.002
The NHS provides access to dietitians and lifestyle programmes that can support your journey towards better liver health
US$ 21.29
US$ 28.90
US$ 21.99
US$ 22.91
US$ 22.89
